With 29 Candidates Advancing, NASH Race May Hinge On Long-Duration Data
Even with market estimates that NASH drugs eventually could command sales of $35 billion a year, some of the candidates and companies now competing in the space will have to be weeded out.
You may also be interested in...
The failure of Tobira's cenicriviroc to meet its primary endpoint in the CENTAUR study has raised some concerns in South Korea over the prospects for a combo therapy with Dong-A ST's evogliptin. But the two firms are sticking to their clinical development plans based on the positive secondary endpoint outcome in the study.
Gilead spent less than $338m for the coupon entitling it to a speedier FDA review, down at least $12m from AbbVie's high-water purchase price almost a year ago.
The biotech argues that success in reducing fibrosis is more important than the failed primary endpoint measuring NAFLD activity score improvement – and also meets FDA's expectations – but the firm is taking a beating nonetheless.